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AnalgesicAbstract The aim of this study was to design and synthesize pharmaceutical agents containing
imidazolidine heterocyclic ring in the hope of developing potent, safe and orally active anti-in-
ﬂammatory agents. A number of substituted-imidazolidine derivatives (3a–k) were synthesized
starting from ethylene diamine and aromatic aldehydes. The imidazolidine derivatives (3a–k) were
investigated for their anticipated anti-inﬂammatory, and analgesic activity in Wistar albino rats and
Swiss albino mice, respectively. Bioactivity score, molecular and pharmacokinetic properties of the
imidazolidine derivatives were calculated by online computer software programs viz.
Molinspiration and Osiris property explorer. The results of biological testing indicated that among
the synthesized compounds only three imidazolidine derivatives namely 4-[1,3-Bis(2,6-
Synthesis, molecular properties, toxicity and biological evaluation of imidazolidine derivatives 105dichlorobenzyl)-2-imidazolidinyl]phenyl-diethylamine (3g), 4-[1,3-Bis(3-hydroxy-4-methoxyben-
zyl)-2-imidazolidinyl]phenyl-diethylamine (3i) and 4-(1,3-Bis(4-methoxybenzyl)-4-methylimidazo-
lidin-2-yl)-phenyl-diethylamine (3j) possess promising anti-inﬂammatory and analgesic actions.
Additionally these derivatives displayed superior GI safety proﬁle (low severity index) with respect
to the positive control, Indomethacin. All synthesized compounds showed promising bioactivity
score for drug targets by Molinspiration software. Almost all the compounds were predicted to
have very low toxicity risk by Osiris online software. Compound number (3i) emerged as a potential
candidate for further research as it obeyed Lipinski’s rule of ﬁve for drug likeness, exhibited promis-
ing biological activity in-vivo and showed no risk of toxicity in computer aided screening.
ª 2015 The Authors. Production and hosting by Elsevier B.V. on behalf of King Saud University. This is
an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Inﬂammation is a normal, natural protective and defense
mechanism of the organism to tissue injury caused by various
factors which include physical trauma, injurious stimuli,
chemical action or microbial infections (Ashley et al., 2012).
It is a very common symptom of many chronic diseases such
as arthritis, osteoarthritis, inﬂammatory bowel disease, and
chronic asthma which put enormous burden on the economy
of the countries. The prevalence of inﬂammatory diseases is
on rise across the world, mostly affecting elderly population
(Gautam and Jachak, 2009). Few epidemiological studies
conducted elsewhere have also linked inﬂammation to patho-
genesis of stroke, cardiovascular diseases, various types of can-
cer and to some extent neurodegenerative diseases. Mantovani
and Pierotti in 2008 reported that inﬂammatory reactions and
underlying infections are involved in 15–20% of all cancer
deaths (Mantovani and Pierotti, 2008).
Nonsteroidal anti-inﬂammatory drugs (NSAIDs) are the
most commonly prescribed medicines for the management
and treatment of various inﬂammatory conditions. These
drugs interfere with the production of lipid autacoids known
as prostaglandins (PGs), which play an important role in elicit-
ing inﬂammatory reactions and its sign and symptoms
(Ricciotti and Fitzgerald, 2011). NSAIDs block the biosynthe-
sis of PGs primarily by inhibiting the arachidonic acid
metabolism via inhibition of several enzymes involved in their
synthesis including cyclooxygenase enzyme (COX-1 and COX-
2) (Tan et al., 1992). Commonly used NSAIDs exhibit higher
selectivity toward COX-1, an enzyme that is involved in the
cytoprotection of the gastrointestinal tract (GIT), than COX-
2 which is principally responsible to cause inﬂammation. A
majority of the commonly used NSAIDs are non selective
inhibitors of both the isozyme forms of cyclooxygenase and
thus are associated with undesirable GI effects such as gastric
irritation, ulceration, bleeding and renal disorders (Allison
et al., 1992; Agnihotri et al., 2010). In order to overcome GI
problems, highly selective COX-2 inhibitors (celecoxib, rofe-
coxib, etc.) were developed and marketed as gastro-protective
NSAIDs (Lanza, 1998). However, long term use of some
selective COX-2 inhibitors has shown potential limitations
including cardiovascular complications, aggravation of ulcers
among high-risk patients, delay in healing process of gastro-
duodenal ulcers, prostacyclin deﬁciency leading to thrombosis
and kidney toxicity (Verrico et al., 2003; Buttgereit et al.,
2001). Hence, selective COX-2 inhibitors because of their high
cost and undesirable side effects are not the ideal candidatesfor the treatment/management of various chronic inﬂamma-
tory disorders and therefore, efforts should be made for the
development of new orally active, potent, improved and safer
NSAIDs with low or no GI side effects.
Imidazolidines (saturated imidazoles), also known as
tetrahydroimidazoles are biologically active nitrogen contain-
ing heterocyclic moiety which have been reported to shown
wide array of signiﬁcant bioactivities such as anti-inﬂam-
matory, analgesic, a-adrenergic receptor agonist, antimicrobial,
antiparasitic, oral hypoglycemic and anticonvulsant activities
(Marki et al., 1984; Sharma and Khan, 2001; Caterina et al.,
2008; Saczewski et al., 2009; Neves et al., 2010; Robert et al.,
2010). They have also been considered as important scaffolds
and intermediates for designing and synthesis of medicinal com-
pounds with potential cyclooxygenase-2 (COX-2) inhibition
activity (Patel et al., 2004). Several substituted-imidazolidine
derivatives have been shown to be potential anti-edema agents
in animal models of inﬂammation. Khan and Chawla, reported
them to be promising group of NSAIDs with potential anti-in-
ﬂammatory activities (Khan and Chawla, 2002).
Literature survey revealed that imidazolidine, a versatile
moiety, could be a possible pharmacophore in designing safer
anti-inﬂammatory medicinal agents (Khan and Chawla, 2002;
Sharma and Khan, 2001; Khan and Gupta, 2003). In contin-
uation of our work on this moiety (Khan et al., 2012;
Husain et al., 2013), it was thought-out to study some new
4-[1,3-bis(substituted-benzyl)-2-imidazolidinyl]phenyl-dialkyl-
amines for their possible in-vivo anti-inﬂammatory plus anal-
gesic actions including gastrointestinal safety (acute
ulcerogenicity). Structure–activity relationships of imidazo-
lidine derivatives were also studied to study the effect of vari-
ous substituents on the biological activity. Oral bioavailability,
toxicity potential and pharmacokinetic proﬁle of synthesized
compounds were also predicted with the aid of computer pro-
grams to select the best candidate(s) among the synthesized
compounds for the drug development.
2. Experimental
2.1. Chemistry
Melting points of the synthesized compounds were determined
using open capillary tubes on a liquid parafﬁn bath and are
uncorrected. The chemical reactions progress was monitored
on silica gel G coated TLC plates in the benzene-ethanol
(8:2) solvent system. Compounds on TLC were spotted by
exposing to iodine vapors or under UV light. The IR spectra
106 A. Husain et al.of the title compounds (in KBr pellets) were recorded on a
Thermo Nicolet avatar 330-FT-IR spectrophotometer. 1H
and 13CNMR spectra of all the prepared compounds were
recorded on a Bruker DPX-300 MHz in CDCl3; chemical shift
(d) values are reported in parts per million (ppm). The
abbreviations used to describe the splitting pattern are as
follows: s for singlet; bs for broad singlet, d for doublet; dd
for double doublet; t for triplet; m for multiplet. Mass spectra
of the synthesized compounds were recorded on LCMS/MS
(Perkin–Elmer and LABINDIA, Applied Bio-system). The
Perkin–Elmer 240 analyzer was used for elemental analysis
of the compounds. The elemental analysis was found within
the array of ±0.4% for each element analyzed (C, H, N).
We used dry solvents throughout the experiments.
Compounds were synthesized as per the reported methods
(Husain et al., 2013), and the synthetic protocol is presented
in Scheme 1.2.2. Synthesis of substituted ethane 1,2 diamines
2.2.1. General procedure for synthesis of N1,N2-bis(substituted-
benzylidene)ethane-1,2-diamines 1a-j
A mixture of an aromatic aldehyde (0.005 mol), ethylenedia-
mine/1,2-diaminopropane (0.006 mol) and dry benzene
(15 mL) with few molecular sieves (4 A˚) was reﬂuxed in a
Dean–Stark assembly. After the removal of water, the reaction
mixture was reﬂuxed for another 6 h to complete the reaction.CHO
A
Aromatic aldehyde
+
Substituted 
Ethylenediamine
(i)
Reagents and conditions:
(i) Dry benzene, refluxed azeotropically, Dean Stark apparat
(ii) Methanol, Dichloromethane, Sodium borohydride, Stirrin
(iii) Ethanol, p-Dialkylamino benzaldehyde, Mechanical sha
Comp R                                A                R'
3a            2-CH3                                  H C2H5
3b            2-NO2                                 H               C2H5
3c            3-NO2                                 H               C2H5
3d            3-Br                           H                C2H5
3e            3-OH                          H               C2H5
3f             2-Cl; 4-Cl                  H               C2H5
3g            2-Cl; 6-Cl H               C2H5
3h            3-OCH3; 4-OCH3      H               C2H5
3i             3-OH; 4-OCH3             H               C2H5
3j             4-OCH3                    CH3            C2H5
3k            4-OCH3                           CH3            CH3
R
H2N-CH2-CH-NH2
R
Scheme 1 Protocol for synthesAfter successful completion of the reaction, the extra amount
of benzene was distilled off to obtain a solid which was crystal-
lized using methanol to give TLC pure compounds 1a–j.
2.2.1.1. N1,N2-bis(2-Methylbenzylidene)ethane-1,2-diamine 1a.
Yield: 78%, m.p. 122–123 C. 1H NMR (CDCl3) d= 2.31
(s, 6H, 2xCH3), 3.77 (s, 4H, 2xCH2), 6.73-7.44 (m, 8H, 2xH-
3,4,5,6), 8.31 (s, 2H, aldimine protons).
2.2.1.2. N1,N2-bis(2-Nitrobenzylidene)ethane-1,2-diamine 1b.
Yield: 82%, m.p. 140–142 C. 1H NMR (CDCl3) d= 3.96
(s, 4H, 2xCH2), 7.18–7.89 (m, 8H, 2xH-3,4,5,6), 8.73 (s, 2H,
aldimine protons).
2.2.1.3. N1,N2-bis(3-Nitrobenzylidene)ethane-1,2-diamine 1c.
Yield: 76%, m.p. 131–133 C. 1H NMR (CDCl3) d= 3.93
(s, 4H, 2xCH2), 7.23–8.21 (m, 8H, 2xH-2,4,5,6), 8.68 (s, 2H,
aldimine protons).
2.2.1.4. N1,N2-bis(3-Bromobenzylidene)ethane-1,2-diamine 1d.
Yield: 73%, m.p. 105–106 C. 1H NMR (CDCl3) d= 3.99
(s, 4H, 2xCH2), 7.14–7.98 (m, 8H, 2xH-2,4,5,6), 8.59 (s, 2H,
aldimine protons).
2.2.1.5. N1,N2-bis(3-Hydroxybenzylidene)ethane-1,2-diamine
1e. Yield: 68%, m.p. 136–138 C. 1H NMR (CDCl3)
d= 3.86 (s, 4H, 2xCH2), 6.98–7.56 (m, 8H, 2xH-2,4,5,6),
8.28 (s, 2H, aldimine protons), 10.32 (bs, 1H, OH).CH N
CH2 CH
N CH
A
CH2 NH
CH2 CH
HN CH2
A
N N
CH2CH2
N
R'R'
A
(1a-j)
(2a-j)
(ii)
(iii)
us; 
g, 15-18oC
ker
(3a-k)
R
R
R
R
R
is of title compounds (3a–k).
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1f. Yield: 77%, m.p. 119–120 C. 1HNMR (CDCl3) d= 3.90
(s, 4H, 2xCH2), 7.34–7.88 (m, 6H, 2xH-3,5,6), 8.63 (s, 2H,
aldimine protons).2.2.1.7. N1,N2-bis(2,6-Dichlorobenzylidene)ethane-1,2-diamine
1g. Yield: 75%, m.p. 140–142 C. 1H NMR (CDCl3) d= 3.88
(s, 4H, 2xCH2), 7.41–7.95 (m, 6H, 2xH-3,4,5), 8.24 (s, 2H,
aldimine protons).2.2.1.8. N1,N2-bis(3,4-Dimethoxybenzylidene)ethane-1,2-dia-
mine 1h. Yield: 81%, m.p. 152–153 C. 1H NMR (CDCl3)
d= 3.84 (s, 16H, 4xOCH3 + 2xCH2), 6.82 (d, J= 8 Hz,
2H, 2xH-5), 7.15 (dd, J= 2 Hz, 8 Hz, 2H, H2x6), 7.46 (d,
J= 2 Hz, 2H, 2xH-2), 8.26 (s, 2H, aldimine protons).2.2.1.9. N1,N2-bis(3-Hydroxy-4-methoxybenzylidene)ethane-
1,2-diamine 1i. Yield: 74%, m.p. 121–124 C. 1H NMR
(CDCl3) d= 3.82 (s, 6H, 2xOCH3), 3.95 (s, 4H, 2xCH2),
6.85 (d, J= 8 Hz, 2H, 2xH5), 7.13 (dd, J= 2 Hz, 8 Hz, 2H,
2xH6), 7.48 (d, J= 2 Hz, 2H, 2xH2), 8.18 (s, 2H, aldimine
protons), 10.21 (bs, 1H, OH).2.2.1.10. N1,N2-bis(4-methoxystyryl)propane-1,2-diamine 1j.
Yield: 86%, m.p. 85–86 C. 1H NMR (CDCl3) d= 1.37 (d,
3H, CH3), 3.75 (s, 6H, 2xOCH3), 3.91 (s, 4H, 2xCH2), 6.86-
7.61 (m, 8H, 2xH-2,3,5,6), 8.08 & 8.16 (s, each, 2H, aldimine
protons).2.3. Reduction of N1,N2-bis(substituted-benzylidene)ethane-1,2-
diamines to get N1,N2-bis(substituted-benzyl)ethane-1,2-
diamines 2a–j
The compound 1a–j (0.003 mol) was dissolved in a mixture of
methanol (15 mL) and dichloromethane (10 mL). Afterward, a
solution of NaBH4 (0.013 mol) in sodium hydroxide solution
(2 N; 1 mL) was slowly added with constant shaking. The reac-
tion mixture was stirred for 5 h at the temperature maintained
between 15 and 18 C. Upon completion of reaction, the
remaining solvent was removed by distillation. The residue
so obtained was diluted with water and ﬁnally extracted with
ether. Anhydrous sodium sulfate was used to dry the extracted
ether layer. The dried layer was ﬁltered and distilled off to get
the desired compounds 2a–j. The products obtained were pale
yellow–brown colored viscous oils which were found pure on
TLC examination. The compounds were utilized as such for
the preparation of ﬁnal compounds.2.3.1. N1,N2-bis(2-Methylbenzyl)ethane-1,2-diamine 2a
Pale yellow viscous oil, Yield: 62%, 1H NMR (CDCl3)
d= 2.33 (s, 6H, 2xCH3), 2.85 (s, 4H, 2xCH2), 3.68 (s, 4H,
2xNCH2, benzyl), 6.81–7.53 (m, 8H, 2xH-3,4,5,6), 9.31 (bs,
2H, 2xNH).2.3.2. N1,N2-bis(2-Nitrobenzyl)ethane-1,2-diamine 2b
Light brown viscous oil, Yield: 74%, 1H NMR (CDCl3)
d= 3.02 (s, 4H, 2xCH2), 3.89 (s, 4H, 2xNCH2, benzyl),
7.65-8.23 (m, 8H, 2xH-3,4,5,6), 9.43 (bs, 2H, 2xNH).2.3.3. N1,N2-bis(3-Nitrobenzyl)ethane-1,2-diamine 2c
Brown viscous oil, Yield: 66%, 1H NMR (CDCl3) d= 3.02 (s,
4H, 2xCH2), 3.76 (s, 4H, 2xNCH2, benzyl), 7.72–8.19 (m, 8H,
2xH-2,4,5,6), 9.46 (bs, 2H, 2xNH).
2.3.4. N1,N2-bis(3-Bromobenzyl)ethane-1,2-diamine 2d
Dark yellow viscous oil, Yield: 70%, 1H NMR (CDCl3)
d= 3.03 (s, 4H, 2xCH2), 3.74 (s, 4H, 2xNCH2, benzyl),
7.33-7.85 (m, 8H, 2xH-2,4,5,6), 9.13 (bs, 2H, 2xNH).
2.3.5. N1,N2-bis(3-Hydroxybenzyl)ethane-1,2-diamine 2e
Pale yellow viscous oil, Yield: 64%, 1H NMR (CDCl3)
d= 2.83 (s, 4H, 2xCH2), 3.81 (s, 4H, 2xNCH2, benzyl),
6.83–7.56 (m, 8H, 2xH-2,4,5,6), 9.38 (bs, 2H, 2xNH).
2.3.6. N1,N2-bis(2,4-Dichlorobenzyl)ethane-1,2-diamine 2f
Yellow viscous oil, Yield: 72%, 1H NMR (CDCl3) d= 3.10 (s,
4H, 2xCH2), 3.75 (s, 4H, 2xNCH2, benzyl), 7.31–7.94 (m, 6H,
2xH3,5,6), 9.22 (bs, 2H, 2xNH).
2.3.7. N1,N2-bis(2,6-Dichlorobenzyl)ethane-1,2-diamine 2g
Dark yellow viscous oil, Yield: 68%, 1H NMR (CDCl3)
d= 3.08 (s, 4H, 2xCH2), 3.78 (s, 4H, 2xNCH2, benzyl),
7.29-7.87 (m, 6H, 2xH-3,4,5), 9.17 (bs, 2H, 2xNH).
2.3.8. N1,N2-bis(3,4-Dimethoxybenzyl)ethane-1,2-diamine 2h
Pale yellow viscous oil, Yield: 65%, 1H NMR (CDCl3)
d= 2.86 (s, 4H, 2xCH2), 3.69 (s, 4H, 2xNCH2, benzyl),
6.96–7.56 (m, 6H, 2xH-2,5,6), 9.25 (bs, 2H, 2xNH).
2.3.9. N1,N2-bis(3-Hydroxy-4-methoxybenzyl)ethane-1,2-
diamine 2i
Yellow viscous oil, Yield: 67%, 1H NMR (CDCl3) d= 2.88 (s,
4H, 2xCH2), 3.73 (s, 4H, 2xNCH2, benzyl), 6.92-7.58 (m, 6H,
2xH-2,5,6), 9.19 (bs, 2H, 2xNH).
2.3.10. N1,N2-bis(4-methoxybenzyl)propane-1,2-diamine 2j
Red viscous oil, Yield: 58%, 1H NMR (CDCl3) d= 1.29 (m,
3H, CH3), 3.69 (bs, 3H, CH2 + CH), 3.78 (s, 4H, 2xNCH2,
benzyl), 6.88-7.54 (m, 8H, 2xH-2,3,5,6), 9.89 (bs, 2H, 2xNH).
2.4. General procedure for the synthesis of substituted-
imidazolidine derivatives 3a–k
The compound 2a–j (2 mmol) was dissolved in absolute
ethanol (15 mL), and p-diethyl/dimethyl-aminobenzaldehyde
(2 mmol) was added to it. This reaction mixture was properly
shaken for 5 h using mechanical shaker and then kept in a
refrigerator for whole night. The reaction mixture was concen-
trated to reduce to half of its volume and was transferred to ice
cold water which gave a solid mass. It was ﬁltered and then
crystallized by methanol to get TLC pure compounds 3a–k.
2.4.1. 4-[1,3-Bis(2-methylbenzyl)-2-imidazolidinyl]phenyl-
diethylamine 3a
Yield: 68%, m.p. 118-120 C. IR (KBr: cm1): 3110 (CAH),
1583 (CAN), 1605 (C‚C).1H NMR (CDCl3) d= 1.12 (t,
6H, 2xCH3CH2), 2.02 (s, 6H, 2xCH3), 2.39 & 3.07 (m, each,
2xCH2, imidazole ring), 3.15 & 3.73 (d, each, 4H, 2xCH2,
108 A. Husain et al.benzyl), 3.27 (q, 4H, 2x CH3CH2), 3.67 (s, 1H, CH, imidazole
ring), 6.64 (d, J= 8 Hz, 2H, H3,5, p-diethylamino ring), 6.91–
7.26 (m, 8H, 2xH3,4,5,6, o-tolyl), 7.42 (d, J= 8 Hz, 2H, H-2,6,
p-diethylamino ring). 13C NMR (CDCl3) d= 14.71
[N(CH2CH3)2], 22.43 (CH3), 40.86 [N(CH2CH3)2], 50.25 (C4/
5), 56.27 (C6/68), 88.66 (C2), 112.18 (C9/98/11/118), 112.28
(C38 8/58 8), 126.85 (C7/78), 127.82 (C188), 128.21 (C8/88), 129.34
(C12/128), 130.38 (C28 8/68 8), 141.86 (C10/108), 149.35 (C48 8).
MS [EI] m/z 427 (M+). Elemental analysis (C29H37N3);
Calcd. C, 81.45; H, 8.72; N, 9.83; found: C, 81.21; H, 8.68;
N, 9.76.
2.4.2. 4-[1,3-Bis(2-nitrobenzyl)-2-imidazolidinyl]phenyl-
diethylamine 3b
Yield: 55%, m.p. 164-166 C. IR (KBr, cm-1): 3114 (CAH),
1589 (CAN), 1604 (C‚C). 1H NMR (CDCl3) d= 1.14 (t,
6H, 2x CH3CH2), 2.38 & 3.12 (m, each, 4H, 2xCH2, imidazole
ring), 3.23 & 3.75 (d, each, 4H, 2xCH2, benzyl), 3.31 (q, 4H, 2x
CH3CH2), 3.70 (s, 1H, CH, imidazole ring), 6.66 (d, J= 8 Hz,
2H, H3,5, p-diethylamino ring), 7.03-7.43 (m, 8H, 2H2,3,5,6,
p-nitrophenyl), 7.46 (d, J= 8 Hz, 2H, H2,6, p-diethylamino
ring). 13C NMR (CDCl3) d= 14.53 [N(CH2CH3)2], 40.75
[N(CH2CH3)2], 50.88 (C4/5), 56.34 (C6/6
8), 88.62 (C2),
112.31 (C38 8/58 8), 111.86 (C11/118), 112.53 (C9/98), 126.79 (C7/
78), 127.34 (C188), 128.98 (C12/128), 129.12 (C8/88), 131.03
(C28 8/68 8), 146.36 (C10/108), 150.12 (C48 8). MS [EI] m/z 489
(M+), 490. Elemental analysis (C27H31N5O4); Calcd. C,
66.24; H, 6.38; N, 14.31; found: C, 66.18; H, 6.42; N, 14.26.
2.4.3. 4-[1,3-Bis(3-nitrobenzyl)-2-imidazolidinyl]phenyl-
diethylamine 3c
Yield: 51%, m.p. 141–142 C. IR (KBr, cm1); 3109 (CAH),
1595 (CAN), 1602 (C‚C). 1H NMR (CDCl3) d= 1.15 (t,
6H, 2xCH3CH2), 2.41 & 3.16 (m, each, 4H, 2xCH2, imidazole
ring), 3.19 & 3.81 (d, each, 4H, 2xCH2, benzyl), 3.33 (q, 4H, 2x
CH3CH2), 3.67 (s, 1H, CH, imidazole ring), 6.73 (d, J= 8 Hz,
2H, H3,5, p-diethylamino ring), 7.08-7.46 (m, 8H, 2x m-chlor-
ophenyl), 7.44 (d, J= 8 Hz, 2H, H2,6, p-diethylamino ring).
13C NMR (CDCl3) d= 14.61 [N(CH2CH3)2], 40.68
[N(CH2CH3)2], 50.55 (C4/5), 56.41 (C6/6
8), 88.37 (C2),
112.84 (C388/588), 113.67 (C8/88), 126.65 (C7/78), 127.06 (C12/
128), 127.32 (C18 8), 128.13 (C9/98), 129.17 (C11/118), 130.34
(C28 8/68 8), 131.21 (C10/108), 151.16 (C48 8). MS [EI] m/z 489
(M+), 490. Elemental analysis (C27H31N5O4); Calcd. C,
66.24; H, 6.38; N, 14.31; found: C, 66.31; H, 6.15; N, 14.28.
2.4.4. 4-[1,3-Bis(3-bromobenzyl)-2-imidazolidinyl]phenyl-
diethylamine 3d
Yield: 62%, m.p. 162-164 C. IR (KBr, cm1); 3115 (CAH),
1593 (CAN), 1601 (C‚C). 1H NMR (CDCl3) d= 1.13 (t,
6H, 2xCH3CH2), 2.42 & 3.15 (m, each, 4H, 2xCH2, imidazole
ring), 3.18 & 3.69 (d, each, 4H, 2xCH2, benzyl), 3.31 (q, 4H, 2x
CH3CH2), 3.66 (s, 1H, CH, imidazole ring), 6.71 (d, J= 8 Hz,
2H, H3,5, p-diethylamino ring), 7.02-7.43 (m, 8H, 2x
m-bromophenyl), 7.46 (d, J= 8 Hz, 2H, H2,6, p-diethylamino
ring). 13C NMR (CDCl3) d= 14.58 [N(CH2CH3)2], 40.72
[N(CH2CH3)2], 50.58 (C4/5), 56.35 (C6/6
8), 87.86 (C2),
112.04 (C388/588), 114.25 (C8/88), 126.84 (C7/78), 127.13 (C12/
128), 127.15 (C18 8), 128.67 (C9/98), 129.02 (C11/118), 130.18(C28 8/68 8), 133.15 (C10/108), 150.83 (C488). MS [EI] m/z 557
(M+), 555, 558, 559. Elemental analysis (C27H31Br2N3);
Calcd. C, 58.18; H, 5.61; N, 7.54; found: C, 57.86; H, 5.64;
N, 7.32.
2.4.5. 4-[1,3-Bis(3-hydroxybenzyl)-2-imidazolidinyl]phenyl-
diethylamine 3e
Yield: 58%, m.p. 144–146 C. IR (KBr, cm1); 3353 (OH),
3142 (CAH), 1588 (CAN), 1601 (C‚C); 1H NMR (CDCl3)
d= 1.12 (t, 6H, 2xCH3CH2), 2.53 & 3.31 (m, each, 4H,
2xCH2, imidazole ring), 3.16 & 3.81 (m, each, 4H, 2xCH2, ben-
zyl), 3.29 (q, 4H, 2x CH3CH2), 3.62 (s, 1H, CH, imidazole
ring), 6.65-7.38 (m, 12H, 3x phenyl rings). 13C-NMR
(CDCl3) d= 13.97 [N(CH2CH3)2], 40.08 [N(CH2CH3)2],
50.26 (C4/5), 56.18 (C6/68), 88.03 (C2), 112.98 (C38 8/58 8),
113.81 (C8/88), 125.78 (C7/78), 126.35 (C12/128), 126.71
(C18 8), 127.33 (C9/98), 128.16 (C11/118), 129.84 (C28 8/68 8),
132.53 (C10/108), 149.28 (C48 8). MS [EI] m/z 431 (M+, not
observed). Elemental analysis (C27H33N3O2); Calcd. C, 75.14;
H, 7.71; N, 9.74; found: C, 74.96; H, 7.63; N, 9.81.
2.4.6. 4-[1,3-Bis(2,4-dichlorobenzyl)-2-imidazolidinyl]phenyl-
diethylamine 3f
Yield: 70%, m.p. 126-128 C. IR (KBr, cm1); 3124 (CAH),
1589 (CAN), 1602 (C‚C). 1H NMR (CDCl3) d= 1.15 (t,
6H, 2x CH3CH2), 2.43 & 3.16 (m, each, 4H, 2xCH2, imidazole
ring), 3.18 & 3.65 (d, each, 4H, 2xCH2, benzyl), 3.32 (q, 4H, 2x
CH3CH2), 3.67 (s, 1H, CH, imidazole ring), 7.11-7.86 (m, 10H,
3x phenyl ring). 13C NMR (CDCl3) d= 14.63 [N(CH2CH3)2],
40.71 [N(CH2CH3)2], 50.48 (C4/5), 56.22 (C6/6
8), 88.16 (C2),
112.01 (C38 8/58 8), 113.25 (C11/118), 114.68 (C9/98), 116.42 (C8/
88), 125.93 (C7/78), 126.81 (C18 8), 128.97 (C12/128), 129.85
(C28/68 8), 149.73 (C488), 153.91 (C10/108). MS [EI] m/z 537
(M+), 535, 538, 539. Elemental analysis (C27H29Cl4N3);
Calcd. C, 60.35; H, 5.44; N, 7.82; found: C, 60.08; H, 5.26;
N, 7.74.
2.4.7. 4-[1,3-Bis(2,6-dichlorobenzyl)-2-imidazolidinyl]phenyl-
diethylamine 3g
Yield: 64%, m.p. 119–121 C. IR (KBr, cm1); 3127 (CAH),
1586 (CAN), 1601 (C‚C). 1H NMR (CDCl3) d= 1.15 (t,
6H, 2x CH3CH2), 2.44 & 3.18 (m, each, 4H, 2xCH2, imidazole
ring), 3.16 & 3.66 (d, each, 4H, 2xCH2, benzyl), 3.31 (q, 4H, 2x
CH3CH2), 3.65 (s, 1H, CH, imidazole ring), 7.06-7.83 (m, 10H,
3x phenyl ring). 13C NMR (CDCl3) d= 14.63 [N(CH2CH3)2],
40.71 [N(CH2CH3)2], 50.51 (C4/5), 56.57 (C6/6
8), 87.85 (C2),
112.24 (C38 8/58 8), 113.12 (C11/118), 114.85 (C9/98), 115.97 (C8/
88), 125.55 (C7/78), 126.64 (C18 8), 129.71 (C288/688), 131.03
(C12/128), 133.15 (C10/108), 150.76 (C48 8). MS [EI] m/z 537
(M+), 535, 536, 538, 539. Elemental analysis (C27H29Cl4N3);
Calcd. C, 60.35; H, 5.44; N, 7.82; found: C, 60.08; H, 5.26;
N, 7.74.
2.4.8. 4-[1,3-Bis(3,4-dimethoxybenzyl)-2-imidazolidinyl]
phenyl-diethylamine 3h
Yield: 60%, m.p. 132-133 C. IR (KBr, cm1); 3111 (CAH),
1590 (CAN), 1600 (C‚C), 1070 (CAO). 1H NMR (CDCl3)
d= 1.13 (t, 6H, 2xCH3CH2), 2.39 & 3.16 (m, each, 4H,
2xCH2, imidazole ring), 3.08 & 3.75 (d, each, 4H, 2xCH2,
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(s, 1H, CH, imidazole ring), 6.68-7.46 (m, 10H, 3x phenyl
rings). 13C NMR (CDCl3) d= 14.39 [N(CH2CH3)2], 40.53
[N(CH2CH3)2], 50.10 (C4/5), 55.63 (OCH3), 56.64 (C6/6
8),
88.57 (C2), 110.86 (C38 8/58 8), 112.57 (C8/88), 113.22 (C11/118),
120.13 (C12/128), 126.85 (C188), 129.78 (C28 8/68 8), 130.69 (C7/
78), 149.25 (C9/98), 150.83 (C488), 155.63 (C10/108). MS [EI]
m/z 519 (M+). Elemental analysis (C31H41N3O4); Calcd. C,
71.65; H, 7.95; N, 8.09; found: C, 71.38; H, 7.86; N, 8.21.
2.4.9. 4-[1,3-Bis(3-hydroxy-4-methoxybenzyl)-2-
imidazolidinyl]phenyl-diethylamine 3i
Yield: 66%, m.p. 140–142 C. IR (KBr, cm1); 3380 (OH),
3120 (CAH), 1592 (CAN), 1602 (C‚C), 1064 (CAO). 1H
NMR (CDCl3) d= 1.15 (t, 6H, 2xCH3CH2), 2.36 & 3.15 (m,
each, 4H, 2xCH2, imidazole ring), 3.06 & 3.73 (d, each, 4H,
2xCH2, benzyl), 3.35 (q, 4H, 2x CH3CH2), 3.73 (s, 6H,
2xOCH3), 3.62 (s, 1H, CH, imidazole ring), 6.62–7.38 (m,
10H, 3x phenyl rings). 13C NMR (CDCl3) d= 14.37
[N(CH2CH3)2], 40.48 [N(CH2CH3)2], 50.15 (C4/5), 55.58
(OCH3), 56.33 (C6/6
8), 89.14 (C2), 110.79 (C388/588), 111.66
(C8/88), 112.56 (C11/118), 120.25 (C12/128), 127.24 (C188),
130.18 (C288/688), 131.35 (C7/78), 149.18 (C9/98), 150.45 (C488),
156.17 (C10/108). MS [EI] m/z 491 (M+). Elemental analysis
(C29H37N3O4); Calcd. C, 70.85; H, 7.59; N, 8.55; found: C,
70.64; H, 7.38; N, 8.62.
2.4.10. 4-(1,3-Bis(4-methoxybenzyl)-4-methylimidazolidin-2-
yl)-phenyl-diethylamine 3j
Yield: 64%, m.p. 110–112 C. IR (KBr, cm1); 3114 (CAH),
1593 (CAN), 1599 (C‚C), 1074 (CAO). 1H NMR (CDCl3)
d= 0.98 (d, 3H, CH3), 1.13 (t, 6H, 2xCH3CH2), 2.46 (m,
2H, CH2, imidazole ring), 2.89 (m, 1H, CH of imidazole ring
carrying methyl group), 3.31 (q, 4H, 2x CH3CH2), 3.01 &
3.75 (d, 4H, 2xCH2, benzyl), 3.72 (s, 6H, 2xOCH3), 3.78 (s,
1H, CH, imidazole ring), 6.48-6.82 (m, 8H, 2x p-anisyl rings),
6.84 (d, J= 8 Hz, 2H, H3,5, p-diethylamino ring), 7.46 (d,
J= 8 Hz, 2H, H2,6, p-diethylamino ring). 13C NMR
(CDCl3) d= 14.73 [N(CH2CH3)2], 22.46 (CH3), 40.79
[N(CH2CH3)2], 55.46 (C6
8), 56.26 (C6), 57.48 (C4), 58.12
(C5), 88.85 (C2), 55.36 (OCH3), 111.83 (C9/9
8/11/118), 113.16
(C38 8/58 8), 126.87 (C188), 127.63 (C7/78), 128.78 (C8/88/12/128),
129.97 (C28 8/68 8), 150.24 (C48 8), 155.96 (C10/108). MS [EI] m/z
473 (M+). Elemental analysis (C30H39N3O2); Calcd. C,
76.07; H, 8.30; N, 8.87; found: C, 75.83; H, 8.26; N, 8.65.
2.4.11. 4-(1,3-Bis(4-methoxybenzyl)-4-methylimidazolidin-2-
yl)-phenyl-dimethylamine 3k
Yield: 61%, m.p. 92–94 C. IR (KBr, cm1); 3120 (CAH),
1593 (CAN), 1605 (C‚C), 1067 (CAO). 1H NMR (CDCl3)
d= 0.95 (d, 3H, CH3), 2.51 (m, 2H, CH2, imidazole ring),
2.86 (m, 1H, CH of imidazole ring carrying methyl group),
2.93 (s, 6H, 2xCH3), 3.03 & 3.66 (d, 4H, 2xCH2, benzyl),
3.69 (s, 6H, 2xOCH3), 3.75 (s, 1H, CH, imidazole ring),
6.56–6.75 (m, 6H, 2x p-anisyl rings), 6.78 (d, J= 8 Hz, 2H,
H3,5, p-diethylamino ring), 7.44 (d, J= 8 Hz, 2H, H2,6, p-
diethylamino ring). 13C NMR (CDCl3) d= 22.52 (CH3),
40.15 [N(CH3)2], 55.14 (OCH3), 55.53 (C6
8), 56.21 (C6),
57.26 (C4), 59.02 (C5), 89.56 (C2), 112.15 (C9/98/11/118),113.24 (C38 8/588), 125.58 (C18 8), 126.94 (C7/78), 128.05 (C8/88/
12/128), 130.12 (C28 8/68 8), 149.87 (C48 8), 154.52 (C10/108). MS
[EI] m/z 445 (M+). Elemental analysis (C28H35N3O2); Calcd.
C, 75.47; H, 7.92; N, 9.43; found: C, 75.40; H, 7.84; N, 9.66.
2.5. Pharmacology
The approval of the protocol of the animal experiments was
given by the Institutional Animal Ethics Committee (IAEC)
of Jamia Hamdard, New Delhi, India. The synthesized com-
pounds were investigated for their in-vivo anti-inﬂammatory
activity by adopting the method of Winter et al.,(1962).
Those compounds that showed good anti-inﬂammatory activ-
ity (>50%) were additionally evaluated for analgesic activity
(Seigmund et al., 1957) and ulcerogenic actions (Cioli et al.,
1979).
2.5.1. Anti-inﬂammatory activity
The synthesized compounds were evaluated for their anti-
inﬂammatory activity by adopting carrageenan-induced paw
edema method in Wistar albino rats of either sex, weighing
160–200 g. The animals were randomly alienated into twelve
different groups comprising six rats in each group. Group I
(control) received 0.5% carboxymethyl cellulose (CMC) solu-
tion. Group II (standard) received Indomethacin; 20 mg/kg,
p.o. and groups III–XII received test compounds (20 mg/kg,
p.o.). The test compounds and standard drugs were adminis-
tered to all animals and then 30 minute later, an injection of
0.1 mL of 0.1% solution of carrageenan (in sterile 0.9%
NaCl solution) was given by subcutaneous route into the
sub-plantar region of the right hind paw of each rat including
control group. The volume of the animal’s paw was deter-
mined using glass Plethysmometer at 3 h after administration
of carrageenan injection. The percentage inhibition of edema
was calculated using the formula:
Anti inflammatory activityð%inhibitionÞ
¼ ½ðVc  VtÞ=Vc  100 ð1Þ
where Vc = The volume of edema of a control group, and
Vt =The volume of edema of animals in groups treated with
test compounds.
2.5.2. Analgesic activity
The screened compounds which demonstrated good anti-in-
ﬂammatory activity (>50%) were further evaluated for their
analgesic action by acetic acid induced writhing method
(Seigmund et al., 1957). Eight groups of Swiss albino mice
(20–30 g) of either sex were made. There were six animals in
each group. Intra-peritoneal injection of 0.10 mL of 1% solu-
tion of aqueous acetic acid was given to induce writhing in ani-
mals. These animals were habituated for 30 min before acetic
acid injection. The test compounds were administrated orally
at a dose of 20 mg/kg for the evaluation of analgesic activity.
The control group was given CMC suspension. Second group
was given standard drug aspirin and Test compounds sus-
pended in 1.0% CMC at a dose of 20 mg/kg were administered
orally to rest of other groups. Intra-peritoneal injection of
aqueous acetic acid was given to all mice after one hour of
administration of tested drug. Stretching movements compris-
ing of arching of the back, elongation of body and extension of
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acetic acid injection. The analgesic activity of the compounds
was articulated as percentage protection and calculated using
following formula:
Analgesic activityð%ProtectionÞ ¼ ½ðWc WtÞ=Wc  100
where Wc =mean number of writhes of control group, and
Wt =mean number of writhes of test group.
2.5.3. Acute ulcerogenic activity
Acute ulcerogenesis test was performed according to the
method as described by Cioli et al. (1979). Albino rats weigh-
ing about 160–200 g were randomly divided into eight different
groups having six animals in each group. The evaluation of
ulcerogenic activity was carried out after oral administration
of test compounds or indomethacin at the dose of 60 mg/kg
which is 3 times of anti-inﬂammatory dose. The rats of control
group received oral administration of vehicle as a suspension
of 1% CMC. Food was stopped 24 h before administration
of the test compounds, while water was continuously given.
The animals were fed with normal diet after the drug treatment
for the duration of 17 h and then animals were sacriﬁced. The
rats’ stomach was isolated and opened alongside the greater
curvature. The opened stomach was properly washed with
distilled water and cleaned smoothly by sinking into normal
saline. The damage to the mucosal was scrutinized with the
help of a 10· magnifying glass. The following scoring system
was used to assess the mucosal damage for each stomach:
0.5: redness, 1.0: spot ulcers, 1.5: hemorrhagic streaks, 2.0:
ulcers > 3 but < 5, 3.0: ulcers > 5. The severity index of
gastric mucosal damage was calculated by subtracting the
mean score of control group from mean score of each treated
group or severity index of gastric mucosal damage = the mean
score of each treated group minus the mean score of control
group. There was no mucosal damage in the control group
with severity index of 0.00.
2.6. Calculation of pharmacokinetic parameters and toxicity
potential
Chemical structures and SMILES notations of the title com-
pounds were obtained by using ACD labs Chemsketch version
12.0. SMILES notations of the imidazolidine derivatives were
then fed in the online Molinspiration software version 2011.06
(www.molinspiration.com) to calculate various molecular
properties and to predict bioactivity score for drug targets
including enzymes and nuclear receptors, kinase inhibitors,
GPCR ligands, and ion channel modulators. Molecular prop-
erties such as partition coefﬁcient (Log P), Topological polar
surface area (TPSA), hydrogen bond donors and acceptors,
rotatable bonds, number of atoms, molecular weight, and vio-
lations of Lipinski’s rule of ﬁve were calculated to evaluate the
drug likeness of the synthesized compounds (Lipinski et al.,
1997). The bioactivity score and drug likeness properties of
the imidazolidine derivatives were compared with the standard
drugs indomethacin and aspirin. The absorption percentage
(% Ab) was also calculated by the reported method of Zhao
et al. (2002) by using the following formula:
%Ab ¼ 109 ½0:345 TPSAOsiris property explorer (www.organicchemistry.org/prog/
peo/), an online cheminformatics tool, was used to determine
pharmacokinetic parameters such as toxicity potential, solubil-
ity and overall drug-likeness of imidazolidine derivatives. The
results of virtual screening are valued and color coded either
green or red for properties such as effect on reproductive
system, irritant effect and tumorigenicity. Properties shown
in red indicate high risks of undesired effects while a green
color shows drug-conform behavior, compatibility and safety
in-vivo.
2.7. Statistical analysis
All data generated from the animal experiments were calcu-
lated as mean ± SEM. The one-way ANOVA followed by
Dunnett’s multiple comparison test was employed to ﬁnd out
the statistical differences between the treatments and the
standard.
3. Results and discussion
3.1. Chemistry
The title compounds, 4-[1,3-bis(substituted-benzyl)-2-imidazo-
lidinyl]phenyl-dialkylamines (3a–k), were successfully synthe-
sized from N1,N2-bis(substituted-benzyl)ethane-1,2-diamines
(2a–j) which in turn were prepared by the reduction of
N1,N2-bis(substituted-benzylidene)ethane-1,2-diamines (1a–j).
Different steps of synthesis have been shown in the
Scheme 1. In the initial step, appropriate aromatic aldehydes
were reacted azeotropically with ethylenediamine/1,2-diamino-
propane to obtain N1,N2-bis(substituted-benzylidene)ethane-
1,2-diamines (1a–j). In the next step, the reduction of the
compounds (1a–j) in the presence of sodium borohydride
furnished N1,N2-bis(substituted-benzyl)ethane-1,2-diamines
(2a–j). These compounds were oily (viscous) in nature and pale
yellow to brown in color. In the ﬁnal step, the compound 2a–j
was condensed with p-diethyl/dimethyl-aminobenzaldehyde to
obtain the desired imidazolidines (3a–k).
The structures of the prepared compounds were conﬁrmed
with the help of spectral and microanalysis data results. The
IR spectra of imidazolidine derivatives showed absorption
bands (cm1) at 3108–3142 (CAH) and 1583–1595 (CAN).
In general, 1H NMR spectra (PMR) of the desired compounds
revealed the signals of aromatic, diethyl/dimethyl, methylenes
of imidazolidines ring and benzylic methylene protons.
Triplet at around d 1.1 and quartet at d 3.2 revealed the pres-
ence of AN(CH2CH3)2 group. The multiplets at around d 2.4
& 3.1 and a singlet at around d 3.6 accounted for 2xCH2
and CH of imidazolidines ring. Two doublets each at around
d 3.2 and 3.7 indicated the presence of two benzylic methy-
lenes. The three phenyl rings protons are shown in the region
of d 6.5–7.8. An analysis of spectra indicates that the imidazo-
lidines ring methylene protons as well as the benzylic methy-
lene protons are non-equivalent and showed geminal
coupling in PMR. 13C NMR spectral data of the imidazolidine
derivatives revealed peaks around d 14.2 for [N(CH2CH3)2]
and d 40.6 for [N(CH2CH3)2]. Other peaks were shown at
appropriate d-values. Mass spectra of the compounds showed
molecular ion peaks (M+) in reasonable intensities. The
Table 1 Anti-inﬂammatory, analgesic and ulcerogenic activi-
ties of the compounds (3a–k).
Compound Anti-
inﬂammatory
activity %
Inhibitiona
(After 3 h)
Analgesic
activity %
Protectiona
Ulcerogenic
eﬀect (Severity
indexb)
3a 34.18 ± 3.97** nt nt
3b 42.46 ± 2.93** nt nt
3c 45.43 ± 3.54** nt nt
3d 38.85 ± 1.97** nt nt
3e 29.72 ± 2.01** nt nt
3f 53.92 ± 2.14* 40.94 ± 2.05** 0.58 ± 0.23
3g 57.53 ± 2.89 51.44 ± 2.73** 0.91 ± 0.30*
3h 52.22 ± 3.36** 36.23 ± 1.55** 0.67 ± 0.16
3i 64.11 ± 2.19 56.88 ± 3.04** 1.08 ± 0.24*
3j 61.35 ± 3.18 45.65 ± 3.32** 0.75 ± 0.21
3k 54.35 ± 3.00* 42.39 ± 3.21** 0.42 ± 0.15
Control – – 0.00 ± 0.0
Standard 1 67.09 ± 2.74 nt 2.08 ± 0.39**
Standard 2 nt 59.78 ± 2.55 nt
* p< 0.05.
** p< 0.01.
 Standard 1 = Indomethacin; Standard 2 = Aspirin; nt = not
tested.
a Relative to the standard and data were analyzed by one-way
ANOVA followed by Dunnett’s multiple comparison test for
n= 6.
b Relative to control and data were analyzed by one-way
ANOVA followed by Dunnett’s multiple comparison test for
n= 6.
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topic abundances because of chlorine atom(s) presence.
Microanalysis data were found in the range of ±0.4% for
the theoretical numbers of the analyzed elements (C, H, N).Table 2 Drug likeness score for the synthesized imidazolidine deriv
Compound miLog Pa TPSAb n Atoms n ONc
3a 6.256 9.71 32 3
3b 5.276 101.36 36 9
3c 5.324 101.36 36 9
3d 7.025 9.71 32 3
3e 4.448 50.17 32 5
3f 8.022 9.71 34 3
3g 7.974 9.71 34 3
3h 4.748 46.65 38 7
3i 4.133 68.64 36 7
3j 5.898 28.18 35 5
3k 5.146 28.18 33 5
Indomethacin 3.986 68.54 25 5
Aspirin 1.434 63.60 13 4
a Logarithm of partition coefﬁcient between n-octanol and water (miLo
b Topological polar surface area (TPSA).
c Number of hydrogen bond acceptors (n-ON).
d Number of hydrogen bond donors (n-OHNH).
e Number of rotatable bonds (n-rotb).
f Percentage of absorption (%ABS).
g Molecular weight (MW).3.2. Pharmacokinetic parameters and toxicity potential
Lipinski’s rule of ﬁve is commonly used by pharmaceutical
chemists in drug design and development to predict oral
bioavailability of potential lead or drug molecules.
According to Lipinski’s ‘‘rule of ﬁve’’, a candidate molecule
will likely to be orally active, if: i) the molecular weight is
under 500, ii) the calculated octanol/water partition coefﬁcient
(Log P)<5, iii) there were fewer than 5 hydrogen bond donors
(OH and NH groups) and, iv) there are less than ten hydrogen
bond acceptors (notably N and O) (Lipinski et al., 1997). The
molecular properties of imidazolidine derivatives (3a–k) were
calculated by using Molinspiration cheminformatics software
and are presented in Table 2. Compound no 3e and 3i did
not violate any of the Lipinski’s rule of ﬁve, however one vio-
lation was observed for ﬁve compounds (3a, 3b, 3c, 3h and 3j).
All other compounds showed two violations and are expected
to be orally inactive.
Molecular hydrophobicity or lipophilicity is indicated by
Log P or partition coefﬁcient. Log P values of all the title com-
pounds except 3e, 3h and 3i were found to be more than 5 and
are in clear violation of Lipinski’s rule of ﬁve, suggesting poor
permeability across cell membrane. Log P values of indo-
methacin and aspirin, the standard drugs were found to be well
under 5 justifying their oral use. Molecular weight of six
imidazolidine derivatives was found to be less than 500 and
thus these molecules are anticipated to be easily transported,
diffused and absorbed as compared to large molecules.
Number of hydrogen bond acceptors (O and N atoms) and
number of hydrogen bond donors (NH and OH) in the synthe-
sized compounds 3a-k were in accordance with the Lipinski’s
rule of ﬁve i.e. less than 10 and 5 respectively. It can be pre-
dicted that among ten synthesized imidazolidine derivatives,
only compounds 3e and 3i are likely to be orally active as they
obeyed Lipinski’s rule of ﬁve.
Topological polar surface area is very much correlated with
the hydrogen bonding of a molecule and is a very goodatives (3a–k).
n OHNHd n violation n rotbe % ABSf MWg
0 1 8 105.65 427.64
0 1 10 74.03 489.58
0 1 10 74.03 489.58
0 2 8 105.65 557.37
2 0 8 91.69 431.58
0 2 8 105.65 537.36
0 2 8 105.65 537.36
0 1 12 92.96 519.67
2 0 10 85.32 491.63
0 1 10 99.28 473.66
0 1 8 99.28 445.61
1 0 4 85.35 357.79
1 0 3 87.057 180.16
gP).
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imidazolidine derivatives was observed in the range of 9.71–
101.36 A0 and is well below the limit of 160 A0. The percent-
ages of absorption for title compounds calculated from
TPSA ranged between 74.03 and 105.65% and indicated good
oral bioavailability.
The bioactivity scores of title compounds for drug targets
were also predicted by Molinspiration and are presented in
Table 3. A molecule having bioactivity score more than 0.00
is most likely to exhibit considerable biological activities, while
values 0.50 to 0.00 are expected to be moderately active and
if score is less than 0.50 it is presumed to be inactive. The
results clearly reveal that the physiological actions of imidazo-
lidine derivatives might involve multiple mechanisms and
could be due to the interactions with GPCR ligands, nuclear
receptor ligands, and inhibit protease and other enzymes.
The bioactivity score of compounds is suggestive of moderate
interaction with all drug targets. The most promising com-
pounds as per the bioactivity scores were identiﬁed to be 3e,
3i and 3k which are predicted to act by more than three mecha-
nisms (Table 3). The identiﬁed compounds showed better
bioactivity score than aspirin for all drug targets.
Results of toxicity risks and drug score assessment of syn-
thesized imidazolidine derivatives were envisaged by Osiris
property explorer and are presented in Table 4. This online
program predicts on the basis of functional group similarityTable 3 Bioactivity score of the synthesized compounds (3a-k) acc
Compound GPCR ligand Ion channel modulator Kinase inhibit
3a 0.10 0.35 0.26
3b 0.16 0.31 0.31
3c 0.18 0.34 0.31
3d 0.17 0.36 0.29
3e 0.05 0.27 0.21
3f 0.09 0.30 0.25
3g 0.07 0.29 0.21
3h 0.11 0.42 0.23
3i 0.09 0.33 0.20
3j 0.06 0.37 0.27
3k 0.07 0.37 0.27
Indomethacin 0.24 0.31 0.11
Aspirin 0.76 0.32 1.06
Table 4 Drug-likeness/scores and toxicity calculations of imidazoli
Compound Solubility Drug-likeness Drug score
3a 4.56 3.18 0.12
3b 4.79 10.3 0.13
3c 4.79 8.31 0.13
3d 5.54 6.27 .07
3e 3.28 2.96 0.17
3f 6.81 1.97 0.06
3g 6.81 2.6 0.06
3h 3.94 1.16 0.15
3i 3.31 2.07 0.16
3j 4.28 1.69 0.14
3k 3.68 3.23 0.37
Indomethacin 5.4 9.41 0.56
Aspirin 1.93 0.48 0.14of the investigated compound with the extensively in vitro –
and in-vivo studied compounds present in its database. The
results are color coded such as red, green and yellow
(Actelion’s property explorer, 2001). Green color suggests
low toxic potential, yellow means mild toxicity and red color
indicates high probability of toxicity. The results clearly indi-
cated that all compounds except 3k would be safe and expected
to show low or no toxicity regarding tumorigenicity, irritant
effect and effect on reproductive system.
3.3. Pharmacology
Rat paw edema induced by carrageenan is a more frequently
employed experimental animal model to study the in-vivo
anti-inﬂammatory activity of natural or synthetic medicinal
agents (Franzotti et al., 2000; Gupta et al., 2006). Edema
induced by carrageenan involved release of various inﬂamma-
tory mediators but it is predominantly due to release of pros-
taglandins, bradykinins and other related autacoids causing
migration of macrophages and polymorphonuclear neu-
trophils to the site of inﬂammation (Fernandes et al., 2007).
The results of in-vivo anti-inﬂammatory presented in Table 1
indicated that compounds 3g, 3i and 3j possess good anti-
inﬂammatory action which showed 57.53%, 64.11% and
61.35% inhibition, respectively. The activity of these
compounds was comparable to inhibition produced by theording to Molinspiration cheminformatics software.
or Nuclear receptor ligand Protease inhibitor Enzyme inhibitor
0.30 0.18 0.22
0.33 0.20 0.22
0.32 0.22 0.24
0.39 0.24 0.24
0.17 0.13 0.14
0.28 0.18 0.23
0.32 0.16 0.22
0.28 0.18 0.20
0.23 0.18 0.16
0.17 0.09 0.19
0.17 0.06 0.17
0.42 0.11 0.30
0.44 0.82 0.28
dine derivatives (3a-k) based on Osiris property explorer.
Tumorigenic Reproductive eﬀect Irritant eﬀect
Yellow Green Green
Yellow Green Green
Yellow Green Green
Yellow Green Green
Yellow Green Green
Yellow Green Green
Yellow Green Green
Yellow Green Green
Yellow Green Green
Yellow Green Green
Red Green Green
Green Green Green
Red Red Green
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pounds, 3f, 3h and 3k, showed signiﬁcant anti-inﬂammatory
activity with 53.92%, 52.22% and 54.35% inhibition, respec-
tively. Other compounds displayed modest to low activity with
% inhibition in the range of 29.72–45.43%. It can be summar-
ized that the anti-inﬂammatory activity of the synthesized
compounds may be due to the inhibition of inﬂammatory
mediators release and possibly due to the inhibition of cycloox-
ygenase synthesis similar to indomethacin. The results showed
that disubstituted phenyl rings attached to the imidazolidine
ring (3f, 3g, 3h & 3i) exhibited improved activity as compared
to that of the mono-substituted phenyl rings. The induction of
methyl group at 4th position of the imidazolidine ring (3j & 3k)
enhanced the anti-inﬂammatory action. The occurrence of
nitro group (3b & 3c) to the mono-substituted phenyl rings
on the imidazolidine ring demonstrated signiﬁcant activity.
Similar pattern of activity was also observed in analgesic
screening of the compounds.
Compounds (3f, 3g, 3h, 3i, 3j & 3k) which showed good
anti-inﬂammatory activity (>50% inhibition) were also evalu-
ated for their analgesic activity in acetic acid induced writhing
model in mice. The writhing induced by acetic acid is a sensi-
tive method and has been used since long time as a screening
tool to assess analgesics acting on periphery (Hunskaar and
Hole, 1987). The inﬂammatory pain is primarily due to
excitation of pain nerve ending by the release of endogenous
substances (Kulkarni and Jain, 2005).
Two compounds, 3g & 3i, showed good analgesic action
with 51.44% and 56.88% protection, respectively, and their
analgesic activity was almost at par with standard drug,
Aspirin, which showed 59.78% protection. Rest of the com-
pounds illustrated analgesic activity in the range of 36.23–
45.65% protection (Table 1). A signiﬁcant difference
(p< 0.01) was found in the analgesic activity of all tested
compounds.
In ulcerogenic test, the tested compounds (3f, 3g, 3h, 3i, 3j
& 3k) showed reduced ulcerogenic activity (as per severity
index), ranging from 1.08 to 0.42, while the standard drug
indomethacin demonstrated high severity index of 2.08
(Table 1). The results demonstrated that the all the tested com-
pounds were low in their GIT toxicity and are better tolerated
than indomethacin. Compound 3k showed the least sign of GI
toxicity while compound 3i was found to be the most toxic in
synthesized compounds which showed almost double severity
index as compared to 3k. A signiﬁcant difference in ulcero-
genic activity was also observed for compounds 3g and 3i
(p< 0.05). Compound 3i emerged as the most effective anti-
inﬂammatory and analgesic agent but with slightly high
ulcerogenic index with respect to synthesized compounds.
Compound 3j exhibited better anti-inﬂammatory and ulcero-
genic activity but showed weaker analgesic activity in compar-
ison with 3g.4. Conclusions
The present work reports the synthesis, spectral characterization
and biological activities including anti-inﬂammatory, analgesic
and ulcerogenic activities of newly synthesized series of imidazo-
lidine derivatives (3a–k). Anti-inﬂammatory and analgesic
activity results revealed that three compounds, 4-[1,3-Bis(2,
6-dichlorobenzyl)-2-imidazolidinyl]phenyl-diethylamine (3g),4-[1,3-Bis(3-hydroxy-4-methoxybenzyl)-2-imidazolidinyl]phenyl-
diethylamine (3i), and 4-(1,3-Bis(4-methoxybenzyl)-4-methylim-
idazolidin-2-yl)-phenyl-diethylamine (3j), were good in their
bio-actions. Moreover, these new derivatives were also low in
their ulcerogenic action (GIT toxicity) which is a common
unwanted effect of all commonly prescribed NSAIDs. Thus it
could be concluded that compounds containing imidazolidine
ring possess signiﬁcant anti-inﬂammatory and analgesic activi-
ties and these could lead to drug discovery or lead molecule
for anti-inﬂammatory therapy. However, further detailed
investigations such as in-vivo pharmacokinetic proﬁle, toxicity,
mechanism(s), are needed to evaluate their potential of develop-
ing into the therapeutic agents.Acknowledgement
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